Third Wave Technologies reports successful clinical trial
Third Wave Technologies Inc. (Nasdaq: TWTI), which develops molecular diagnostic products for DNA and RNA analysis, reported after Tuesday’s close that its clinical trial for human papillomavirus (HPV) was successful and that it expects to submit the trial results to the U.S. Food and Drug Administration in April. Shares rocketed 40.8%, or $2.90, to $10 in pre-market trading.
For detailed price information and recent news stories about Third Wave Technologies, click TWTI.
